Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study — G. Denise Zielinski (2019) | RDL Network
Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
Research and Practice in Thrombosis and Haemostasis 4(1): 141-153
Article 2019 English
Authors
GZ
G. Denise Zielinski
NR
Nienke van Rein
MT
Martina Teichert
Abstract
1 min read
In contrast to vitamin K antagonists (VKA), direct oral anticoagulants (DOAC's) are not strictly monitored and dose titrated by anticoagulation clinics in the Netherlands. This may affect drug persistence of atrial fibrillation (AF) patients, whom often require lifelong treatment.
G. Denise Zielinski, Nienke van Rein, Martina Teichert, Frederikus A. Klok, Frits R. Rosendaal, F.J.M. van der Meer, Menno V. Huisman, Suzanne C. Cannegieter, Willem M. Lijfering
Daniele Pastori, Professor Gregory Lip, Alessio Farcomeni, Francesco Del Sole, Angela Sciacqua, Francesco Perticone, Rossella Marcucci, Elisa Grifoni, Pasquale Pignatelli, Francesco Violi, Mirella Saliola, Marco Casciaro, Danilo Menichelli, Francesco Cribari, Alberto Paladino, Rony Gingis, Marta Novo, Vittoria Cammisotto, Cristina Nocella, Simona Bartimoccia, Roberto Carnevale,
Jan Steffel, Rónán Collins, Matthias Antz, Pieter Cornu, Lien Desteghe, Karl Georg Hæusler, Jonas Oldgren, Holger Reinecke, Vanessa Roldán, Nigel Rowell, Peter Sinnaeve, Thomas Vanassche, Tatjana Potpara, A. John Camm, Hein Heidbüchel, Professor Gregory Lip, Thomas Deneke, Nikolaos Dagres, Giuseppe Boriani, Tze-Fan Chao, Eue-Keun Choi, Mellanie True Hills,
.jpg){kind=small}
Discussion(0)
No comments yet. Be the first to comment.